SCYNEXIS Presents Positive Interim Data of Ibrexafungerp for Refractory Candida Infections from Ongoing Phase 3 FURI Study During the Mycoses Study Group Education and Research Consortium (MSGERC) Biennial Meeting
Approximately 83% of FURI patients with refractory Candida infections had positive clinical outcomes, defined as complete/partial response or no disease progression . Data from the ongoing Phase... | September 8, 2022
Source: marketscreener.com